Comparison of Outcomes after Device Closure and Medication Alone in Patients with Patent Foramen Ovale and Cryptogenic Stroke in Korean Population
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: To compare the effectiveness of device closure and medical therapy in prevention of recurrent embolic event in the Koreanpopulation with cryptogenic stroke and patent foramen ovale (PFO). Materials and Methods: Consecutive 164 patients (men: 126 patients, mean age: 48.1 years, closure group: 72 patients, medical group: 92 patients) were enrolled. The primary end point was a composite of death, stroke, transient ischemic attack (TIA), or peripheralembolism. Results: Baseline characteristics were similar in the two groups, except age, which was higher in the medical group (45.3±9.8 vs. 50.2±6.1, p<0.0001), and risk of paradoxical embolism score, which was higher in the closure group (6.2±1.6 vs. 5.7±1.3, p=0.026). On echocardiography, large right-to-left shunt (81.9% vs. 63.0%, p=0.009) and shunt at rest/septal hypermobility (61.1% vs. 23.9%, p<0.0001) were more common in the closure group. The device was successfully implanted in 71 (98.6%) patients. The primary end point occurred in 2 patients (2 TIA, 2.8%) in the closure group and in 2 (1 death, 1 stroke, 2.2%) in the medical group. Event-free survival rate did not differ between the two groups. Conclusion: Compared to medical therapy, device closure of PFO in patients with cryptogenic stroke did not show difference in reduction of recurrent embolic events in the real world’s setting. However, considering high risk of echocardiographic findings in the closure group, further investigation of the role of PFO closure in the Asian population is needed.
Abstract
Purpose: To compare the effectiveness of device closure and medical therapy in prevention of recurrent embolic event in the Koreanpopulation with cryptogenic stroke and patent foramen ovale (PFO). Materials and Methods: Consecutive 164 patients (men: 126 patients, mean age: 48.1 years, closure group: 72 patients, medical group: 92 patients) were enrolled. The primary end point was a composite of death, stroke, transient ischemic attack (TIA), or peripheralembolism. Results: Baseline characteristics were similar in the two groups, except age, which was higher in the medical group (45.3±9.8 vs. 50.2±6.1, p<0.0001), and risk of paradoxical embolism score, which was higher in the closure group (6.2±1.6 vs. 5.7±1.3, p=0.026). On echocardiography, large right-to-left shunt (81.9% vs. 63.0%, p=0.009) and shunt at rest/septal hypermobility (61.1% vs. 23.9%, p<0.0001) were more common in the closure group. The device was successfully implanted in 71 (98.6%) patients. The primary end point occurred in 2 patients (2 TIA, 2.8%) in the closure group and in 2 (1 death, 1 stroke, 2.2%) in the medical group. Event-free survival rate did not differ between the two groups. Conclusion: Compared to medical therapy, device closure of PFO in patients with cryptogenic stroke did not show difference in reduction of recurrent embolic events in the real world’s setting. However, considering high risk of echocardiographic findings in the closure group, further investigation of the role of PFO closure in the Asian population is needed.
참고문헌 (18)
- Lechat P, "Prevalence of patent foramen ovale in patients with stroke", N Engl J Med, 318, pp.1148~1152 (1988)
- Furlan AJ, "Closure or medical therapy for cryptogenic stroke with patent foramen ovale", N Engl J Med, 366, pp.991~999 (2012)
- Meier B, "Percutaneous closure of patent foramen ovale in cryptogenic embolism", N Engl J Med, 368, pp.1083~1091 (2013)
- Carroll JD, "Closure of patent foramen ovale versus medical therapy after cryptogenic stroke", N Engl J Med, 368, pp.1092~1100 (2013)
- Agarwal S, "Metaanalysis of transcatheter closure versus medical therapy for patent foramen ovale in prevention of recurrent neurological events after presumed paradoxical embolism", JACC Cardiovasc Interv, 5, pp.777~789 (2012)
- Wolfrum M, "Stroke prevention by percutaneous closure of patent foramen ovale: a systematic review and meta-analysis", Heart, 100, pp.389~395 (2014)
- Ikeda Y, "Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial", JAMA, 312, pp.2510~2520 (2014)
- Mas JL, "Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both", N Engl J Med, 345, pp.1740~1746 (2001)
- Kent DM, "The risk of paradoxical embolism (RoPE) study: developing risk models for application to ongoing randomized trials of percutaneous patent foramen ovale closure for cryptogenic stroke", Trials, 12, pp.185~ (2011)
- Thaler DE, "Recurrent stroke predictors differ in medically treated patients with pathogenic vs. other PFOs", Neurology, 83, pp.221~226 (2014)
- Paciaroni M, "Risk of recurrent cerebrovascular events in patients with cryptogenic stroke or transient ischemic attack and patent foramen ovale: the FORI (Foramen Ovale Registro Italiano) study", Cerebrovasc Dis, 31, pp.109~116 (2011)
- Mazzucco S, "A model of multi-disciplinary approach to the diagnosis and treatment of young patients with cryptogenic stroke and patent foramen ovale", Cardiol Young, 22, pp.327~334 (2012)
- Ueshima H, "Cardiovascular disease and risk factors in Asia: a selected review", Circulation, 118, pp.2702~2709 (2008)
- Wahl A, "Longterm propensity score-matched comparison of percutaneous closure of patent foramen ovale with medical treatment after paradoxical embolism", Circulation, 125, pp.803~812 (2012)
- Lansberg MG, "Antithrombotic and thrombolytic therapy for ischemic stroke: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines", Chest, 141(2 Suppl), pp.e601S36S~ (2012)
- Homma S, "Effect of medical treatment in stroke patients with patent foramen ovale: patent foramen ovale in Cryptogenic Stroke Study", Circulation, 105, pp.2625~2631 (2002)
- Kitsios GD, "Patent foramen ovale closure and medical treatments for secondary stroke prevention: a systematic review of observational and randomized evidence", Stroke, 43, pp.422~431 (2012)
- Steinberg DH, "Patent foramen ovale closure: past, present and future", Expert Rev Cardiovasc Ther, 5, pp.881~891 (2007)